Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Queensland Health
McKesson
Harvard Business School
Chinese Patent Office
AstraZeneca
Moodys
Baxter
Fish and Richardson
Daiichi Sankyo

Generated: October 22, 2017

DrugPatentWatch Database Preview

Lupin Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for LUPIN LTD, and when can generic versions of LUPIN LTD drugs launch?

LUPIN LTD has one hundred and seven approved drugs.

There is one US patent protecting LUPIN LTD drugs on LUPIN LTD drugs in the past three years. There are fifteen tentative approvals on LUPIN LTD drugs.

There are two patent family members on LUPIN LTD drugs in two countries and one hundred and eighty-six supplementary protection certificates in thirteen countries.

Summary for Applicant: Lupin Ltd

International Patents:2
US Patents:1
Tradenames:89
Ingredients:75
NDAs:107
Drug Master File Entries: (click here to view)184
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd
DOXYCYCLINE HYCLATE
doxycycline hyclate
TABLET;ORAL208818-002Sep 27, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
ARMODAFINIL
armodafinil
TABLET;ORAL200751-003Nov 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL205217-001Dec 18, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
LEVONORGESTREL AND ETHINYL ESTRADIOL
ethinyl estradiol; levonorgestrel
TABLET;ORAL091440-001Oct 23, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
amlodipine besylate; hydrochlorothiazide; valsartan
TABLET;ORAL200797-001Jun 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
amlodipine besylate; hydrochlorothiazide; valsartan
TABLET;ORAL200797-005Jun 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
LAMOTRIGINE
lamotrigine
TABLET;ORAL078691-003Jun 1, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL090246-001May 15, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
TELMISARTAN AND AMLODIPINE
amlodipine besylate; telmisartan
TABLET;ORAL201586-004Jan 8, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
TRAMADOL HYDROCHLORIDE
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200503-003Aug 29, 2011AB1RXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for LUPIN LTD drugs

Drugname Dosage Strength Tradename Submissiondate
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
cefixime
for Oral Suspension500 mg/5 mL
SUPRAX
7/22/2014

Non-Orange Book Patents for Lupin Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,241,905Pharmaceutical compositions of Cefixime► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Lupin Ltd Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2007119249► Subscribe
Germany112007000920► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Lupin Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/009United Kingdom► SubscribePRODUCT NAME: VALSARTAN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE 36983.00.00 19960513; DE 36983.01.00 19960513; UK 00001/0218 19961016; UK 00001/0219 19961016; UK 00001/0225 19961016
C0043France► SubscribePRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1730131/02Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
C/GB08/018United Kingdom► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
2016017Lithuania► SubscribePRODUCT NAME: SAKUBITRILAS/VALSARTANAS; REGISTRATION NO/DATE: EU/1/15/1058 20151119
00028Netherlands► SubscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
2009 00015Denmark► SubscribePRODUCT NAME: EN KOMBINATION AF OLMESARTANMEDOXOMIL, EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT OG AMLODIPIN-BESILAT; NAT. REG. NO/DATE: MT 42061, 42062, 42063 20081120; FIRST REG. NO/DATE: NL RVG 100984 20080819
496Luxembourg► SubscribePRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Harvard Business School
Farmers Insurance
Moodys
Colorcon
Deloitte
McKesson
Healthtrust
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot